Does Aetna (CVS Health) Cover Vyleesi (Bremelanotide)?

What Vyleesi Is and Why Coverage Is Complicated

Bremelanotide (brand name Vyleesi) is a subcutaneous melanocortin receptor agonist approved by the FDA on June 21, 2019, for the treatment of generalized, acquired HSDD in premenopausal women. It is self-injected into the abdomen or thigh at least 45 minutes before anticipated sexual activity, with a maximum frequency of once per 24 hours and no more than one dose per day [1]. The FDA label explicitly excludes use in postmenopausal women or men [1].

HSDD affects roughly 10% of adult women in the United States, making it one of the most common female sexual dysfunctions [2]. Despite that prevalence, only two FDA-approved pharmacologic options exist: flibanserin (Addyi, approved 2015) and bremelanotide (Vyleesi, approved 2019). Insurers, including Aetna, classify both as specialty drugs because of their list prices and narrow indicated populations. That classification triggers mandatory prior authorization programs that screen for appropriate diagnosis, patient age, and treatment history before the claim is paid.

Aetna's coverage of Vyleesi sits under Clinical Policy Bulletin guidelines that the insurer updates periodically. The core tension is that Aetna (like most large commercial carriers) wants documented evidence of HSDD severity and prior exposure to behavioral or psychological treatment before approving a $1,200-per-month specialty drug [3]. Prescribers who understand those specific documentation requirements in advance see substantially higher first-pass approval rates.

The RECONNECT Trial: The Clinical Foundation Aetna Relies On

Aetna's prior authorization criteria for Vyleesi are grounded in the published clinical evidence, so understanding that evidence helps prescribers frame their PA letters accurately. The key RECONNECT program consisted of two identical phase 3, randomized, placebo-controlled trials (Study 301 and Study 302) published together in Obstetrics and Gynecology in 2019 [4].

The combined population across both trials was 1,267 premenopausal women with generalized, acquired HSDD confirmed by the Decreased Sexual Desire Screener and baseline electronic diary data. Bremelanotide 1.75 mg subcutaneously produced a statistically significant increase in the number of satisfying sexual events: 25% of treated women achieved a meaningful increase vs. 17% on placebo (P<0.001 for the co-primary endpoint of desire, P<0.01 for distress reduction) [4]. The Female Sexual Function Index desire domain score improved by 0.6 points more than placebo, and the Female Sexual Distress Scale-Desire/Arousal/Orgasm score decreased by 4.0 points more than placebo [4].

The most common adverse effect was nausea (40% of treated patients vs. 1% placebo), which was transient but contributed to a 15.5% discontinuation rate in active-treatment arms [4]. Transient blood pressure increases of approximately 2 mmHg systolic and 1 mmHg diastolic were also observed, which is why Aetna's PA criteria screen for uncontrolled hypertension as a contraindication [1].

Guideline bodies have taken note. The International Society for the Study of Women's Sexual Health (ISSWSH) published a process-of-care algorithm for HSDD stating that "pharmacological therapy is appropriate when HSDD causes personal distress and non-pharmacological approaches have been insufficient" [5]. That language maps directly onto the step-therapy framing Aetna uses in its benefit review.

Aetna's Prior Authorization Criteria for Vyleesi

Approval requires satisfying every criterion in Aetna's medical necessity policy. Missing even one item causes a denial that must then be reversed on appeal.

Diagnosis criteria. The member must carry a confirmed DSM-5-consistent diagnosis of generalized, acquired HSDD. Situational HSDD (desire problems limited to specific partners or contexts) does not qualify under current Aetna policy because it was not the population studied in RECONNECT [4]. The prescribing clinician must document the acquisition date (i.e., the point at which the patient's previous adequate sexual desire declined) and confirm the disorder is not attributable solely to another medical condition, a relationship factor, or a medication side effect [3].

Age and menopausal status. The patient must be premenopausal. Aetna will request laboratory confirmation if clinical notes are ambiguous. The FDA label contraindication for postmenopausal women is reflected verbatim in Aetna's coverage policy [1].

Step therapy. At least one trial of a non-pharmacological intervention, most commonly individual or couples psychotherapy, sex therapy, or a structured mindfulness-based program, must be documented in the clinical record before Vyleesi will be approved. The required duration of that prior therapy varies by plan but is typically a minimum of 8 weeks. This mirrors guidance from the American College of Obstetricians and Gynecologists (ACOG), which states that "psychological and relationship factors should be addressed as part of comprehensive care for HSDD" [6].

Exclusion of contraindications. The prescriber must confirm the absence of cardiovascular disease with elevated risk, uncontrolled hypertension (defined as resting BP >150/95 mmHg), or concurrent use of naltrexone, which significantly reduces bremelanotide efficacy due to opioid receptor antagonism [1].

Prescriber specialty. Most Aetna plans require the prescribing clinician to be an OB-GYN, urogynecologist, reproductive endocrinologist, or sexual medicine specialist. Primary care prescriptions are not automatically rejected, but they face a higher scrutiny bar and should include a specialist consultation note when possible.

Authorization periods are typically 12 months for the initial approval. Renewals require documentation of patient response, defined as at least a subjective improvement in satisfying sexual events or distress scores, plus continued absence of contraindications [3].

Step Therapy: What Counts as Adequate Prior Treatment

Step therapy for Vyleesi is narrower than the multi-drug step therapy common for other drug classes. Aetna does not require a trial of flibanserin (Addyi) before approving Vyleesi. That distinction matters clinically because flibanserin is a daily oral CNS-acting agent with a different mechanism (serotonin receptor modulation) and a different adverse-effect profile, and many patients or clinicians prefer the as-needed dosing schedule of bremelanotide [7].

What Aetna does require is documented behavioral or psychological treatment. Acceptable forms include:

• Six or more sessions of sex therapy or individual psychotherapy with HSDD as the documented focus.
• An 8-week mindfulness-based cognitive behavioral program specifically addressing sexual desire.
• Documented participation in couples counseling where sexual dysfunction was a primary treatment goal.

Progress notes from the therapist, or a summary letter, must be included in the PA submission. A patient statement alone is not sufficient. The minimum session count and duration are the most common documentation gaps that result in step-therapy denials that could have been avoided.

If the patient has a documented psychiatric contraindication to psychotherapy, or lives in a geographic area with no accessible qualified therapist (which Aetna defines as no provider within 30 miles accepting new patients on the member's plan), a medical exception to the step-therapy requirement may be filed simultaneously with the initial PA request [3].

How to Submit a Prior Authorization That Gets Approved

Submitting a complete PA packet on the first attempt reduces the average time to approval from 14 days to 5 to 7 business days based on insurer processing benchmarks [8]. The following documents should accompany every initial Vyleesi PA:

1. A letter of medical necessity on letterhead, written by the prescriber, citing the DSM-5 HSDD diagnosis with onset date, the absence of situational triggers, and the distress the condition causes the patient.
2. Office visit notes documenting baseline sexual function, ideally using a validated instrument such as the Female Sexual Function Index or the Female Sexual Distress Scale-Desire/Arousal/Orgasm.
3. Therapy or behavioral treatment records showing at least 8 weeks of participation, with therapist name, NPI, session dates, and documented focus on sexual desire.
4. A medication reconciliation list confirming the absence of naltrexone, opioids, or other interacting agents.
5. A current blood pressure reading from within the prior 60 days confirming BP is below the 150/95 mmHg threshold.
6. A copy of the FDA-approved indication from the Vyleesi prescribing information, to preemptively address any non-medical-necessity objections.

Aetna's PA portal accepts electronic submissions through NaviMedix/AuthPortal or by fax. Phone submissions are accepted for urgent requests but must be followed by written documentation within 48 hours. Urgent authorization requests, which apply when a clinical urgency exists, are adjudicated within 72 hours under Aetna's utilization management standards and CMS requirements for Medicare Advantage plans [9].

What to Do When Aetna Denies Vyleesi Coverage

Denials fall into three categories: medical necessity denials, step-therapy denials, and administrative denials. Each requires a different response strategy.

Medical necessity denial. The denial letter will cite the specific clinical criteria not met. Request the full Clinical Policy Bulletin number and the specific language from the coverage policy. Resubmit with additional clinical documentation addressing each unmet criterion. A peer-to-peer review call between the prescriber and the Aetna medical director reviewing the case resolves a significant share of medical necessity denials at this stage. The prescriber should request this call proactively rather than waiting for Aetna to offer it [10].

Step-therapy denial. If the behavioral treatment record was incomplete, obtain an updated summary letter from the therapist and resubmit. If step therapy is genuinely not medically appropriate (e.g., documented anxiety disorder preventing therapy engagement), file a step-therapy exception simultaneously with the appeal, citing the exception criteria in the plan's Evidence of Coverage document [3].

Administrative denial. These result from missing prior authorization numbers, incorrect diagnosis codes, or formulary tier mismatches. Correct the administrative error and resubmit; most administrative denials are resolved within 5 business days without requiring a formal appeal.

If the first-level internal appeal is denied, the member has the right to an external independent review under state insurance regulations and, for self-funded ERISA plans, under federal law. External reviewers overturn insurer denials in approximately 39 to 45% of cases for specialty drugs when the prescriber submits complete clinical documentation [11]. The prescriber's letter for external review should directly quote the RECONNECT trial data and the ISSWSH guideline recommendation to establish clinical consensus behind the prescription [4,5].

State-level insurance commissioners can be contacted if an insurer fails to comply with appeal timelines. For Aetna fully insured commercial plans, applicable state prompt-pay and appeal laws set the outer boundary of permissible review periods [12].

Formulary Tier and Out-of-Pocket Cost With Aetna Coverage

On most Aetna commercial plans, Vyleesi sits on Tier 3 (preferred brand) or Tier 4 (non-preferred specialty), depending on the specific plan design. Tier 4 specialty drugs typically carry a 20% to 40% coinsurance rather than a fixed copay [13]. At a $1,200 monthly list price, a 30% coinsurance means a $360 monthly member cost before any deductible applies.

Aetna's Open Access Managed Choice and Elect Choice PPO plans apply specialty drug deductibles separately in some states, meaning the first fill could be at full cost until that deductible clears. Members should call the Member Services number on their ID card and ask specifically: "Is bremelanotide on my formulary, what tier, is there a separate specialty deductible, and is there a quantity limit?" Those four questions, asked directly, give the full financial picture before the prescription is filled.

Cost-sharing assistance programs exist. AMAG Pharmaceuticals (now under Palatin Technologies licensing arrangements) has offered a manufacturer savings card that brings the member cost to as low as $0 for the first prescription and caps ongoing monthly cost for eligible commercially insured patients. This card is not valid for Medicare Part D, Medicaid, or any state or federal program [14]. Eligibility criteria and available amounts change periodically; current details are posted at the manufacturer's patient support program page.

Vyleesi and Weight Loss: Clearing Up a Common Misconception

Aetna does not cover Vyleesi for weight loss. Bremelanotide acts on melanocortin-4 receptors, and other melanocortin-pathway agonists such as setmelanotide (Imcivree) are approved for specific genetic obesity syndromes. Bremelanotide's FDA indication is limited to HSDD in premenopausal women. Any PA request framed around weight management would be denied on indication grounds, and off-label use for obesity is not supported by any published controlled trial [1,15]. Patients asking about melanocortin-based weight management should be directed to discussions of setmelanotide or approved GLP-1 receptor agonists such as semaglutide (Wegovy) or tirzepatide (Zepbound), which have extensive controlled-trial evidence for weight reduction [16].

Specific Documentation Checklist for Prescribers

Submitting incomplete documentation is the single most preventable cause of Vyleesi denials. Every PA package should include a signed attestation that the following have been confirmed:

• DSM-5 HSDD diagnosis: generalized and acquired subtype confirmed.
• Onset of acquired HSDD documented with approximate date.
• Premenopausal status confirmed (laboratory or clinical basis stated).
• Distress confirmed using a validated scale (FSDS-DAO or FSFI desire subscale).
• At least 8 weeks of behavioral/psychological treatment documented with session dates.
• Absence of cardiovascular contraindications documented (BP reading included).
• Absence of naltrexone or interacting opioid medications confirmed.
• Prescriber specialty or consultation note included.

A complete submission matching all eight points gives the reviewing Aetna medical director everything needed to approve without follow-up. Missing even one item creates a reviewable gap that can stall or deny the claim.

The FDA label for bremelanotide 1.75 mg specifies that patients should self-inject no more than one dose per anticipated sexual activity and should not use the drug more than once in 24 hours [1]. PA approvals typically reflect this frequency limitation; prescriptions written for quantities exceeding one dose per day will be rejected at the pharmacy under quantity-limit edits regardless of PA approval [13].